First patient enrolled in GOG-3133/ FRAmework-01 phase 3 study evaluating sofetabart mipitecan (LY4170156), a novel ADC targeting folate receptor alpha (FRα), in recurrent ovarian cancer
Business Announcement
Updates every hour. Last Updated: 27-Dec-2025 23:11 ET (28-Dec-2025 04:11 GMT/UTC)